We are delighted to share that our CEO Dr. Yildiz was invited by Permides to present our EU funded project to customize screening and docking software for our protein-protein drug discovery platform as a case study presentation at BioEurope. Our project was selected as it exemplifies solutions for addressing relevant value chain challenges via novel biopharma - IT collaborations. BioEurope 2017 in Berlin is Europe’s largest Partnering conference in the biopharma space.
Martinsried, Germany and Sankt Augustin, Germany, July 25, 2017 — Avergen Pharmaceutical GmbH (APG) and BioSolveIT announce today that they are backed by a PERMIDES grant approval from the European Union to conduct their collaboration in costumizing a drug screening platform.
Bayern Innovativ is Bavaria's organisation for innovation, technology and knowledge transfer. The grant supports our validation study for the small molecule drug discovery platfrom.
On 31.03.2017 APG signed a cooperation agreement with the Helmholtz Institute in Munich. We are excited to engage in this scientifically challenging project jointly with expirienced scientists from the Helmholtz Institute.
Dr. Yildiz was part of two industry and academic expert panels discussing carrier paths for German scientists working in North America.